More Product Recalls at J&J - Analyst Blog

Johnson & Johnson (JNJ) announced yet another product recall recently. This time round, McNeil Consumer Healthcare said that it is voluntarily recalling all lots of Rolaids Extra Strength Softchews, Rolaids Extra Strength plus Gas Softchews, and Rolaids Multi-Symptom plus Anti-Gas Softchews.

The recall relates to products distributed in the US. The product recall was based on complaints regarding the presence of foreign materials like metal and wood particles, in the product.

In addition to recalling the product, Johnson & Johnson also suspended production and said that production will not be commenced until corrective actions are taken.

Product recalls at Johnson & Johnson have become a regular feature with the company having initiated several recalls in 2010. Earlier this month, Johnson & Johnson-Merck Consumer Pharmaceuticals, Co. recalled twelve Mylanta liquid products and one AlternaGel liquid product from the US and Puerto Rico. This product recall was announced just a few days after the previous recall which was related to Tylenol cold multi-symptom liquid products.

Prior to the Tylenol recall, Johnson & Johnson had recalled all lots of children's Benadryl Allergy Fastmelt tablets (cherry and grape flavors) distributed in the US, Belize, Barbados, Canada, Puerto Rico, St. Martin and St. Thomas. The company also recalled all lots of junior strength Motrin caplets, 24 count, from the US market.

Moreover, the company recalled one product lot of Rolaids extra strength softchews (cherry flavor) from the US market. While the Rolaids product recall was due to complaints regarding an uncharacteristic consistency or texture, the company said that the other two product recalls were not quality-related.

Product Recalls Hit OTC Segment Performance

Back-to-back product recalls over the course of the year have adversely affected sales of Johnson & Johnson's consumer healthcare segment. Third quarter Consumer segment sales declined 10.6% to $3.6 billion, with OTC pharmaceutical and nutritional sales declining 19.4%. The product recall and the suspension of manufacturing at the Fort Washington, Pennsylvania plant resulted in a $240 million negative impact on revenues.

In Jan 2010, Johnson & Johnson had announced the recall of Tylenol, Motrin and Benadryl that were sold in the US, the United Arab Emirates (UAE) and Fiji. The product recall was initiated following complaints from customers regarding an unusual smell.

In July 2010, Johnson & Johnson recalled 21 lots of certain over-the-counter (OTC) medicines being sold in the US, Fiji, Guatemala, Dominican Republic, Puerto Rico, Trinidad & Tobago, and Jamaica. The recalled medicines included Benadryl, Tylenol (including children's Tylenol) and Motrin.

Although Johnson & Johnson has started shipping one of the recalled products, we believe the company will not be in a position to resume normal supply of all the recalled products before the first quarter of 2011. Meanwhile, the Fort Washington plant, which was shut down, is not expected to be operational until late 2011. Johnson & Johnson is also facing legal action related to the product recall.

Other product recalls at Johnson & Johnson include the Aug 2010 recall of two hip replacement systems - the ASR XL Acetabular System and DePuy ASR Hip Resurfacing System. Johnson & Johnson also received a warning letter from the US Food and Drug Administration (FDA) regarding the marketing of its Corail Hip System for unapproved uses.

The company also recalled contact lenses from several countries in Asia and Europe. In Sep 2010, Johnson & Johnson along with Amgen (AMGN) recalled certain lots of Epogen and Procrit due to the possible presence of thin glass flakes in the vials.

Neutral on Johnson & Johnson

We currently have a Neutral recommendation on Johnson & Johnson, which is supported by a Zacks #3 Rank (short-term “Hold” rating). We believe Johnson & Johnson's diversified business model, lack of cyclicality and strong financial position are helping it pave its way through tough situations.

 
AMGEN INC (AMGN): Free Stock Analysis Report
 
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
 
Zacks Investment Research